In this case-based activity, Dr. Harrison Farber takes learners through the differential diagnosis and treatment of two cardiopulmonary patients. Discussion topics include differential diagnostic procedures, guideline recommendations, and therapy selection.
With the expanding use of SGLT2 inhibitors beyond glucose control, this AI-driven activity will inform clinicians about the available evidence assessing their efficacy and safety in CKD, renoprotective benefits in patients with CKD with and without T2DM, evolving practice standards, and their relevance to patient care.
The goal of this program is to improve the knowledge and competence of cardiologists, internists, hospitalists, and other clinicians on new and emerging treatment strategies to reduce HF-related hospitalization and death.
In this series, Dr. John B. Buse, Dr. Kathleen Dungan, and Dr. Christian T. Ruff present patient cases and share their personal approaches to reducing the risk of cardiovascular disease in diabetic patients. Using real-world evidence, they review cardiovascular risk stratification, the efficacy and safety of GLP-1 RA and cardiovascular outcomes trials, and COVID-19 implications as they develop a comprehensive treatment plan for a patient with cardiovascular risk factors.